Live Breaking News & Updates on Marissa Samuels

Stay updated with breaking news from Marissa samuels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for ...

STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical ....

United States , Marissa Samuels , Joe Ciaffoni , Christopher James , Collegium Pharmaceutical Inc , Us Drug Enforcement Agency , Corporate Communications , Hikma Pharmaceuticals United States Inc , Hikma Pharmaceuticals United States , Nucynta Franchise , Chief Executive Officer , Collegium Pharmaceutical , Private Securities Litigation Reform Act , Enforcement Agency , Annual Reports , Quarterly Reports ,

Collegium Pharma (COLL) Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA for Nucynta and Nucynta ER

Collegium Pharma (COLL) Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA for Nucynta and Nucynta ER
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Marissa Samuels , Christopher James , Joe Ciaffoni , Us Drug Enforcement Agency , Corporate Communications , Hikma Pharmaceuticals United States Inc , Collegium Pharmaceutical Inc , Collegium Pharmaceutical , Hikma Pharmaceuticals United States , Nucynta Franchise , Chief Executive Officer , Private Securities Litigation Reform Act , Enforcement Agency , Annual Reports , Quarterly Reports ,

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

STOUGHTON, Mass., April 25, 2024 Collegium Pharmaceutical, Inc. , a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical. ....

United States , Marissa Samuels , Christopher James , Collegium Pharmaceutical Inc , Corporate Communications , Call Information , Collegium Pharmaceutical ,

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified speci. ....

United States , New York , Marissa Samuels , Christopher James , Collegium Pharmaceutical Inc , York Mellon Trust Company , Exchange Commission , Corporate Communications , Company Annual Reports On Form , Convertible Senior Notes Due , Redemption Date , Redemption Price , New York Mellon Trust Company , Depository Trust Company , New York City , Conversion Agent , Whole Fundamental , Common Stock , Collegium Pharmaceutical , Private Securities Litigation Reform Act , Annual Reports , Quarterly Reports ,

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – . ....

United States , Marissa Samuels , Colleen Tupper , Christopher James , Joe Ciaffoni , Corporate Communications , While The Company , Drug Administration , Us Court , Us Drug Enforcement Agency , Collegium Pharmaceutical Inc , Generated Record Quarterly , Full Year Net Revenue , Achieved Quarterly , Delivered Record Quarterly , Full Year Adjusted , Cash Equivalents , Marketable Securities , Conference Call Scheduled , Chief Executive Officer , Chief Financial Officer , Patent Trial , Appeal Board , Nucynta Franchise , Product Revenues , Adjusted Operating Expenses ,